Status of Injectafer lawsuits 2022
https://www.medlegal360.com/injectafer-lawsuits-trials-bring-hope/ An intravenous (IV) iron replacement therapy called Injectafer (ferric carboxymaltose) is used to treat iron deficiency anaemia (IDA). Once within the body, it was made to release iron gradually, potentially lowering the possibility of side effects and delivering more iron in only two doses. The interval between the two doses should be seven days. Itching, rashes, allergic skin reactions, wheezing, shock, low blood pressure, loss of consciousness, and even death among users are all possible side effects of injectafer. Vifor Pharmaceuticals is a manufacturer of Injectafer in Switzerland. In some nations, it is offered under the brand name Ferinject. American Regent, formerly known as Luitpold Pharmaceuticals, distributes it in the US. Due to manufacturing issues, the FDA also rejected the application that was submitted in 2011. On July 25, 2013, the FDA only accepted the NDA when Luitpold resubmitted it. Injectafe...